Brief: GenSight Biologics Updates On Operations In Context Of COVID-19

Gensight Biologics SA

06/04/2020 06:38

April 6 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * GENSIGHT BIOLOGICS PROVIDES UPDATE ON OPERATIONS IN THE
CONTEXT
OF COVID-19
    * ON CORONAVIRUS: CURRENTLY, IMPACT ON OUR OPERATIONS IS
VERY
LIMITED, AND WHILE WE ARE HOPEFUL IT WILL REMAIN SO, WE ARE
PREPARING FOR ALL SCENARIOS
    * COMPANY REMAINS ON TRACK FOR REGULATORY FILING IN EUROPE
(MAA
FILING WITH EMA) IN Q3 2020, WITH POTENTIAL APPROVAL IN H2 2021
    * REFLECT PHASE III TRIAL OF LUMEVOQ® IS FULLY RECRUITED
WITH A
PRIMARY ENDPOINT AT 78 WEEKS
    * PIONEER PHASE I/II CLINICAL TRIAL OF GS030, COMBINING GENE
THERAPY AND OPTOGENETICS FOR TREATMENT OF RETINITIS PIGMENTOSA
(RP), HAS FULLY COMPLETED RECRUITMENT OF SECOND COHORT
    * COMPANY IS FINANCED UNTIL END OF 2020 AND IS INVESTIGATING
OTHER
FINANCING OPTIONS THROUGH DEBT OR EQUITY IN ORDER TO ENSURE THAT
COMPANY IS ABLE TO FACE ANY EVOLUTION OF COVID-19 SITUATION
    * EXPECTS ANY DELAY TO BE OVERCOME AS SOON AS PATIENTS CAN
GET
NORMAL ACCESS TO TREATMENT SITES, WITH NO MATERIAL IMPACT ON
RELATED REVENUES EXPECTED IN 2020

Source text for Eikon:  ID:nBw7G6kqGa 
Further company coverage:  SIGHT.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))